Management of Mast Cell Activation Syndrome

First-Line Treatment Options

The American Academy of Allergy, Asthma, and Immunology (AAAAI) recommends H1-antihistamines as a cornerstone of MCAS management, with ketotifen specifically mentioned as a sedating H1-receptor antagonist that can be compounded as tablets in the US 1, 2
Ketotifen is approved in the US for allergic eye disease but is used off-label for MCAS to treat dermatologic, gastrointestinal, and neuropsychiatric symptoms 1, 2
First-generation H1-antihistamines like ketotifen have limitations due to their sedating effects, which can impair driving ability and potentially lead to cognitive decline, particularly in elderly patients 1, 3
The AAAAI guidelines state that the benefit of ketotifen beyond other antihistamines such as diphenhydramine remains unproven 1, 2

First-line therapy typically includes H1 and H2 receptor antihistamines, with H1 antihistamines (like ketotifen) primarily targeting dermatologic manifestations, tachycardia, and abdominal discomfort 1, 2
Oral cromolyn sodium can be used alongside antihistamines, particularly for gastrointestinal symptoms such as bloating, diarrhea, and abdominal cramps 1, 5
Leukotriene modifiers (montelukast, zafirlukast) or 5-lipoxygenase inhibitor (zileuton) may be added for respiratory or dermatologic symptoms 1, 3
Aspirin may help reduce flushing and hypotension in some patients, particularly those with elevated urinary prostaglandin metabolites, but should be introduced cautiously due to risk of triggering mast cell degranulation 3

Sedating antihistamines like ketotifen may cause cognitive decline, especially in elderly populations 1, 2
Medication trials for MCAS should be conducted in a controlled setting with emergency equipment available 5
Patients should be prescribed epinephrine autoinjectors if they have a history of systemic anaphylaxis or airway angioedema 1, 2
Careful trigger identification and avoidance is crucial for management alongside pharmacologic interventions 5

Serum tryptase levels should be checked within 30-120 minutes of symptom onset during reactions to confirm mast cell activation 5
Response to therapy should be assessed systematically, with consideration for alternative or additional treatments if symptoms persist 1, 2
Full allergic workup including skin testing and specific IgE detection should be conducted to identify potential IgE-mediated hypersensitivities 5